Table 2.
Markers for assessing sample handling variability of plasma within each pre-established proximity extension assay panel
| Panel name | First marker | Second marker | Third marker |
|---|---|---|---|
| Cardiometabolic | MET (ρ = −0.52; p = 0.00573) | TNC (ρ = −0.41; p = 0.0336) | FCGR2A (ρ = −0.36; p = 0.0667) |
| Cardiovascular II | CD40L (ρ = 1.00; p = NA) | SRC (ρ = 0.80; p = 6.44e-07) | HSP27 (ρ = 0.78; p = 1.57e-06) |
| Cardiovascular III | CASP-3 (ρ = 0.88; p = 1.79e-09) | JAM-A (ρ = 0.85; p = 1.48e-08) | PAI (ρ = 0.66; p = 0.000176) |
| Cell regulation | MAP2K6 (ρ = 0.78; p = 2.33e-06) | LRMP (ρ = 0.76; p = 6.91e-06) | METAP1D (ρ = 0.74; p = 1.65e-05) |
| Development | CD69 (ρ = 0.86; p = 7.69e-09) | SNAP29 (ρ = 0.86; p = 9.77e-09) | PPIB (ρ = 0.86; p = 1.12e-08) |
| Immune response | PLXNA4 (ρ = 0.79; p = 1.59e-06) | PRDX5 (ρ = 0.78; p = 2.16e-06) | EIF4G1 (ρ = 0.76; p = 7.8e-06) |
| Inflammation | AXIN-1 (ρ = 0.74; p = 1.76e-05) | STAM-BP (ρ = 0.74; p = 1.82e-05) | ST1A1 (ρ = 0.73; p = 2.06e-05) |
| Metabolism | CA13 (ρ = 0.81; p = 4.07e-07) | PPP1R2 (ρ = 0.77; p = 2.77e-06) | CD2AP (ρ = 0.74; p = 9.59e-06) |
| Neuroexploratory | KIF1BP (ρ = 0.88; p = 1.91e-08) | CD63 (ρ = 0.81; p = 1.51e-06) | PMVK (ρ = 0.81; p = 1.61e-06) |
| Neurology | MANF (ρ = 0.83; p = 2.94e-07) | LAT (ρ = 0.81; p = 7.45e-07) | CLEC1B (ρ = 0.79; p = 2.35e-06) |
| Oncology II | EGF (ρ = 0.91; p = 6.7e-10) | FADD (ρ = 0.72; p = 7.23e-05) | TXLNA (ρ = 0.69; p = 0.000176) |
| Oncology III | GOPC (ρ = 0.81; p = 4.41e-07) | CALCOCO1 (ρ = 0.78; p = 2.7e-06) | CLIP2 (ρ = 0.77; p = 4.19e-06) |
| Organ damage | BANK1 (ρ = 0.79; p = 2.5e-06) | YES1 (ρ = 0.78; p = 4.35e-06) | STX8 (ρ = 0.76; p = 1.03e-05) |
The top three biomarkers for assessing sample handling variability of plasma are listed for each assay panel. Measures were determined and ranked by their predictability of CD40L in a cohort of healthy individuals (n = 28) using a simple linear regression. The Pearson's correlation coefficient (ρ) and probability (p) are listed for each protein.
Abbreviations: BANK1, B cell scaffold protein with ankyrin repeats 1; CA13, carbonic anhydrase 13; CALCOCO1,calcium-binding and coiled-coil domain–containing protein 1; CASP-3, caspase 3; CD2AP, CD2-associated protein; CD40L, cluster differentiation 40 ligand; CD63, cluster differentiation 63; CD69, cluster differentiation 69; CLEC1B, C-type lectin domain family 1, member B; CLIP2, CAP-Gly domain–containing linker protein 2; EGF, epidermal growth factor; EIF4G1, eukaryotic translation initiation factor 4 gamma 1; FADD, Fas-associated protein with death domain; FCGR2A, Fc fragment of IgG receptor 2A; GOPC, Golgi-associated PDZ and coiled-coil motif–containing protein; HSP27, heat shock protein 27; JAM-A, junctional adhesion molecule A; KIF1BP, kinesin family member 1-binding protein; LAT, linker for activation of T cells; LRMP, lymphoid-restricted membrane protein; MANF, mesencephalic astrocyte-derived neurotrophic factor; MAP2K6, mitogen-activated protein kinase kinase 6; MET, mesenchymal epithelial transition; METAP1D, methionyl aminopeptidase type 1D; NA, not available; PAI, plaminogen activator inhibitor; PLXNA4, plexin A4; PMVK, phosphomevalonate kinase; PPIB, peptidylprolyl isomerase B; PPP1R2, protein phosphatase inhibitor 2; PRDX5, peroxiredoxin-5; SNAP29, synaptosomal-associated protein 29; SRC, Src family of protein kinases; ST1A1, sulfotransferase 1A1; STAM-BP, signal-tranducing adaptor molecule binding protein; STX8, syntaxin 8; TNC, tenascin C; TXLNA, taxilin alpha; YES1, YES proto-oncogene 1, Src family tyrosine kinase.